1. Home
  2. KG vs BNR Comparison

KG vs BNR Comparison

Compare KG & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KG

Kestrel Group Ltd.

HOLD

Current Price

$10.38

Market Cap

225.0M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$41.06

Market Cap

216.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KG
BNR
Founded
N/A
2014
Country
Bermuda
China
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
225.0M
216.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KG
BNR
Price
$10.38
$41.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.8K
33.7K
Earning Date
02-15-2026
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
8.50
N/A
Revenue
$26,676,137.00
$75,749,382.00
Revenue This Year
N/A
$136.32
Revenue Next Year
N/A
N/A
P/E Ratio
$1.08
N/A
Revenue Growth
1610.20
5.56
52 Week Low
$8.07
$2.18
52 Week High
$36.80
$34.79

Technical Indicators

Market Signals
Indicator
KG
BNR
Relative Strength Index (RSI) 49.25 78.16
Support Level $8.77 $29.88
Resistance Level $10.74 $34.79
Average True Range (ATR) 0.86 3.64
MACD 0.34 1.39
Stochastic Oscillator 79.96 100.00

Price Performance

Historical Comparison
KG
BNR

About KG Kestrel Group Ltd.

Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: